Bosutinib

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively[1].

Product Specifications

CAS Number

[380843-75-4]

Product Name Alternative

SKI-606

UNSPSC

12352005

Hazard Statement

H319, H413

Target

Autophagy; Bcr-Abl; Src

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Bosutinib.html

Purity

99.96

Solubility

DMSO : ≥ 46 mg/mL

Smiles

CN1CCN(CC1)CCCOC2=C(C=C3C(NC4=CC(OC)=C(C=C4Cl)Cl)=C(C=NC3=C2)C#N)OC

Molecular Formula

C26H29Cl2N5O3

Molecular Weight

530.45

Precautions

H319, H413

References & Citations

[1]Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30 (28) :3486-92.|[2]Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66 (23) :11314-22.